Research ArticleCancer

cIAP1/2 antagonism eliminates MHC class I–negative tumors through T cell–dependent reprogramming of mononuclear phagocytes

See allHide authors and affiliations

Science Translational Medicine  19 May 2021:
Vol. 13, Issue 594, eabf5058
DOI: 10.1126/scitranslmed.abf5058

Log in to view full text

Log in through your institution

Log in through your institution

Stay Connected to Science Translational Medicine

Navigate This Article